| 10/06/2022 |
16:00 às 17:30 |
Módulo pulmão |
16:20 às 16:26 |
9004 - Overall survival from a phase II randomized study of ramucirumab plus pembrolizumab versus standard of care for advanced non–small cell lung cancer previously treated with immunotherapy: Lung-MAP nonmatched substudy S1800A. |
Palestrante |
| 10/06/2022 |
16:00 às 17:30 |
Módulo pulmão |
16:26 às 16:32 |
9002 - KRYSTAL-1: Activity and safety of adagrasib (MRTX849) in patients with advanced/metastatic non–small cell lung cancer (NSCLC) harboring a KRASG12C mutation. |
Palestrante |
| 10/06/2022 |
16:00 às 17:30 |
Módulo pulmão |
16:32 às 16:40 |
102 - Largest evaluation of acquired resistance to sotorasib in KRAS p.G12C-mutated non–small cell lung cancer (NSCLC) and colorectal cancer (CRC): Plasma biomarker analysis of CodeBreaK100. |
Palestrante |
| 10/06/2022 |
16:00 às 17:30 |
Módulo pulmão |
17:00 às 17:30 |
Painel de discussão |
Debatedor |
